INDEPENDENT AUDITOR’S REPORT 2014

AIRXPANDERS, INC.
BALANCE SHEETS
December 31, 2014 and 2013

Assets

Current Assets 2014 2013
Cash and Cash Equivlents $ 1,650,736 $ 5,224,848
Inventory, Net 171,668 -
Prepaid expenses and other current assets 47,043 53,491
Total current assets 1,869,447 5,278,339
Property and equipment, net 155,306 96,283
Other assets 113,044 53,720
Total assets $ 2,137,797 $ 5,428,342

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY

Current liabilities 2014 2013
Current portion of long-term debt, net of discount $ 993,089 $ 1,068,548
Account Payable 401,825 428,514
Accrued Expenses 195,165 146,504
Total current liabilities 1,590,079 1,643,566
Warrant liabilities 164,138 81,744
Long-term debt, less current portion, net of discount 2,570,957 -
Total liabilities $ 4,325,174 $ 1,725,310
Stockholder’s equity
Series E, 8% convertible noncumulative preferred stock, par value $0.001; 50,200,000 and 45,200,000 shares authorized respectively; 49,499,028 and 44,499,028 shares issued and outstanding at December 31, 2014 and 2013, respectively (liquidation preference of $9,899,806 and $8,899,806) $ 44,499 $ 44,499
Series D, 8% convertible noncumulative preferred stock, par value $0.001; 42,176,625 shares authorized; 42,176,625 shares issued and outstanding (liquidation preference of $11,387,689) 42,177 42,177
Series C, 8% convertible noncumulative preferred stock, par value $0.001; 22,725,718 shares authorized; 22,245,718 shares issued and outstanding(liquidation preference of $5,561,430) 22,246 22,246
Series B-1, 8% convertible noncumulative preferred stock, par value $0.001; 9,554,375 shares authorized; 9,554,375 shares issued and outstanding (liquidation preference of $4,549,793) 9,554 9,554
Series B, 8% convertible noncumulative preferred stock, par value $0.001; 3,375,954 shares authorized; 3,125,954 shares issued and outstanding (liquidation preference of $1,488,579) 3,126 3,126
Series A, 8% convertible noncumulative preferred stock, par value $0.001; 4,323,958 shares authorized; 3,908,168 shares issued and outstanding (liquidation preference of $1,861,070) 3,908 3,908
Common stock; par value $0.001, 242,983,187 and and 232,983,187 shares authorized at December 31, 2014 and 2013 respectively; 4,508,329 shares issued and outstanding - -
Additional paid-in capital 33,421,657 32,339,315
Accumulated deficit (35,744,052) (28,766,301)
Total stockholders’ equity (2,187,377) 3,703,032
Total liabilities and stockholders’ equity $ 2,137,797 $ 5,428,342
AIRXPANDERS, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF OPERATIONS
For the Years Ended December 31, 2013 and 2012 and
For the Period from March 17, 2005 (Date of Inception) to December 31, 2013

2014 2013 2012
Operating expenses
Research and development $ 1,193,930 $ 789,022 $ 1,060,005
Clinical trials 2,948,742 3,121,687 3,600,748
Selling, general and administrative 2,228,808 2,011,785 1,913,724
Total Operating loss 6,371,480 5,922,494 6,574,477
Operating loss (6,371,480) (5,922,494) (6,574,477)
Interest expense 561,075 190,196 222,963
Other (income) expense, net 45,196 (46,786) (161,442)
Net Loss $ (6,977,751) $ (6,065,904) $ (6,635,998)